Kingswood Wealth Advisors LLC Has $1.71 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Kingswood Wealth Advisors LLC boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 52.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,840 shares of the medical equipment provider’s stock after acquiring an additional 1,327 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $1,708,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Baystate Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 45 shares during the last quarter. Creekmur Asset Management LLC grew its holdings in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. MCF Advisors LLC increased its position in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares during the period. Able Wealth Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $28,000. Finally, Delos Wealth Advisors LLC boosted its position in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several research analyst reports. Robert W. Baird upped their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Stifel Nicolaus upped their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Morgan Stanley lifted their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Evercore ISI reduced their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $442.30.

Intuitive Surgical Trading Up 0.4 %

Shares of ISRG stock traded up $1.60 during trading hours on Wednesday, hitting $449.26. 1,702,541 shares of the company were exchanged, compared to its average volume of 1,574,361. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $468.78. The business has a 50 day moving average of $433.72 and a two-hundred day moving average of $402.67. The company has a market capitalization of $159.35 billion, a PE ratio of 82.85, a PEG ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the company posted $1.18 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the transaction, the senior vice president now directly owns 883 shares in the company, valued at $343,628.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Robert Desantis sold 239 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $385.55, for a total value of $92,146.45. Following the transaction, the executive vice president now owns 5,507 shares in the company, valued at $2,123,223.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the sale, the senior vice president now directly owns 883 shares in the company, valued at approximately $343,628.28. The disclosure for this sale can be found here. Insiders have sold 16,005 shares of company stock worth $6,894,422 in the last ninety days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.